Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

BMC Psychiatry. 2009 Sep 2;9:54. doi: 10.1186/1471-244X-9-54.

2.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.

J Ment Health Policy Econ. 2003 Jun;6(2):67-75.

PMID:
14578539
3.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, BurĂ³n JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
4.
5.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
6.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
7.

Economic burden of schizophrenia: empirical analyses from a survey in Thailand.

Phanthunane P, Whiteford H, Vos T, Bertram M.

J Ment Health Policy Econ. 2012 Mar;15(1):25-32.

PMID:
22611090
8.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
9.

The functionality and economic costs of outpatients with schizophrenia in Taiwan.

Lee IH, Chen PS, Yang YK, Liao YC, Lee YD, Yeh TL, Yeh LL, Cheng SH, Chu CL.

Psychiatry Res. 2008 Apr 15;158(3):306-15. doi: 10.1016/j.psychres.2006.10.004. Epub 2008 Feb 19.

PMID:
18243334
10.

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.

Glazer WM, Ereshefsky L.

J Clin Psychiatry. 1996 Aug;57(8):337-45.

PMID:
8752015
11.

Outpatient antipsychotic treatment and inpatient costs of schizophrenia.

Marcus SC, Olfson M.

Schizophr Bull. 2008 Jan;34(1):173-80. Epub 2007 Jun 19.

12.

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.

Schizophr Bull. 2008 Nov;34(6):1163-71. Epub 2007 Dec 21.

13.

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.

Gau SS, Chung CH, Gau CS.

J Clin Psychopharmacol. 2008 Jun;28(3):271-8. doi: 10.1097/JCP.0b013e3181723713.

PMID:
18480683
14.

Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.

Bera R, Offord S, Zubek D, Lau G, Lin J, Karson C.

J Clin Psychopharmacol. 2014 Feb;34(1):30-5. doi: 10.1097/JCP.0b013e3182a6082a.

PMID:
24135840
15.

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ.

BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11.

16.

Annual health outcomes and treatment costs for schizophrenia populations.

Mauskopf JA, David K, Grainger DL, Gibson PJ.

J Clin Psychiatry. 1999;60 Suppl 19:14-9; discussion 20-2.

17.

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.

Obradovic M, Mrhar A, Kos M.

Int J Clin Pract. 2007 Dec;61(12):1979-88. Review.

PMID:
17997804
18.

Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group.

J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.

PMID:
22697193
20.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

Supplemental Content

Support Center